SAN DIEGO, CA – In a significant leadership reshuffle, QuidelOrtho Corporation (NASDAQ:QDEL), a prominent player in the in vitro and in vivo diagnostic substances industry, disclosed in a recent SEC filing that it will be parting ways with two of its executive vice presidents. The company announced the departure of Michael S. Iskra, Executive Vice President and Chief Commercial Officer, and Robert J. Bujarski, Executive Vice President and Chief Operating Officer, effective November 15, 2024.
Simultaneously, the company has appointed Philip McLellan as the new Chief Operations Officer, with his tenure beginning on the same date as the aforementioned departures. McLellan, 55, brings a wealth of experience to his new role, having served as QuidelOrtho’s Senior Vice President of Operations since November 2020. His background includes a notable 11-year tenure leading operations teams across various life sciences divisions at Thermo Fisher Scientific (NYSE:), as well as 13 years in global automotive manufacturing roles at Toyota Motor (NYSE:) Manufacturing. McLellan is a Georgia Institute of Technology alumnus with a B.S. in Mechanical Engineering.
As part of his appointment, McLellan will enter into a Severance and Change in Control Agreement, as well as an Indemnification Agreement with QuidelOrtho. Both agreements are consistent with forms previously filed with the SEC. The company has clarified that there are no arrangements or understandings between McLellan and any other persons related to his appointment, no family relationships with other directors or executive officers of the company, and that McLellan is not involved in any transactions requiring disclosure under SEC regulations.
This executive shakeup comes as QuidelOrtho, formerly known as Coronado Topco, Inc., continues to navigate the competitive landscape of the life sciences sector under the organization name 03 Life Sciences. The company’s headquarters are located at 9975 Summers Ridge Road, San Diego, California.
In other recent news, QuidelOrtho Corporation reported significant second quarter revenue of $637 million, surpassing the consensus estimate of $614 million. The company also announced the appointment of Jonathan Siegrist as Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO). QuidelOrtho gained FDA approval for its VITROS syphilis assay, a crucial development in light of the rising syphilis cases in the U.S.
The company is implementing cost-saving measures expected to save approximately $100 million. Analyst firm Craig-Hallum upgraded Quidel (NASDAQ:) shares from Hold to Buy, raising the price target to $57.00, while Citi revised its financial outlook on QuidelOrtho, reducing its price target from $48 to $44.
QuidelOrtho is preparing for the launch of the Savanna instrument and expansion of diagnostic panels, expected to contribute to revenue growth. The company targets an adjusted EBITDA margin in the mid to high 20% range within the next 2-3 years. These recent developments reflect QuidelOrtho’s ongoing efforts to provide advanced diagnostic tools and maintain financial stability.
InvestingPro Insights
As QuidelOrtho Corporation (NASDAQ:QDEL) undergoes this significant leadership transition, investors may find additional context from recent financial data and expert insights valuable. According to InvestingPro data, QuidelOrtho has a market capitalization of $3.01 billion, reflecting its substantial presence in the in vitro diagnostics industry. However, the company’s financial performance has been mixed, with revenue declining by 9.74% over the last twelve months to $2.82 billion.
InvestingPro Tips highlight that QuidelOrtho is currently operating with a significant debt burden, which could be a factor in the company’s strategic decisions, including the recent executive changes. Despite this, analysts predict that the company will be profitable this year, and net income is expected to grow. This positive outlook may provide some reassurance to investors during this period of leadership transition.
It’s worth noting that QuidelOrtho’s stock has experienced a substantial year-to-date price decline of 47.29%, which may reflect market concerns about the company’s performance and outlook. The appointment of Philip McLellan as the new Chief Operations Officer, with his extensive experience in operations management, could be seen as a move to strengthen the company’s operational efficiency and potentially address these challenges.
For investors seeking a more comprehensive analysis, InvestingPro offers 6 additional tips for QuidelOrtho, providing deeper insights into the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
